Preliminary Evidence for Feasibility, Use, and Acceptability of Individualized Texting for Adherence Building for Antiretroviral Adherence and Substance Use Assessment among HIV-Infected Methamphetamine Users
Table 1
Descriptive characteristics of the study groups ().
iTAB ()
Control ()
Demographics
Age; mean (SD)
46.8 (8.3)
52.4 (6.6)
Education; mean (SD)
13.2 (2.7)
14.3 (2.7)
Male; % (#)
90.0% (18)
100.0% (9)
Caucasian; % (#)
55.0% (11)
33.3% (3)
HIV disease characteristics
CD4 count; median [IQR]a
586.5 [140.5, 974.8]
606.5 [198.3, 1053.8]
Nadir CD4 count; median [IQR]b
148 [14.8, 493.8]
235 [153, 362.5]
HIV RNA plasma; median [IQR]c
1.6 [1.6, 1.9]
1.6 [1.6, 3.2]
RNA plasma detectable % (#)d
26.3% (5)
37.5% (3)
AIDS % (#)e
50.0% (2)
50.0% (2)
Time since first positive test; mean (SD)f
125.5 (101.0)
201.1 (104.9)
Meth use characteristics
Age of first use; mean (SD)g
30.0 (12.0)
29.2 (14.6)
Total days used; mean (SD)
1634.8 (2190.8)
1516.2 (1551.5)
Total quantity used; mean (SD)h
1058.7 (1663.4)
1593.4 (2396.4)
Key: a, bNadir CD4 count is self-reported, ; cin log copies/mL, ; 50 cp/mL, ; eAIDS status based on the 1993 CDC classification scheme, ; ftime since first positive test is calculated in months, ;
g, htotal quantity is in grams. Note: no significant differences were observed for any of the reported variables.
